We purchased Shire plc at circa £37 per share when rumours broke that Japanese drugmaker Takeda Pharmaceutical Co was interested in taking over the company.
On 25th April 2018, Takeda and Shire directors finally agreed on a deal that they were both happy to recommend to Shareholders. The purchase price is in flux, as there are two exchange rates involved and some of the consideration offered to Shire shareholders is in Takeda’s shares (0.839 Takeda shares per Shire share).
Takeda’s shares are quoted in Yen, and vary in price as the relative attractiveness of the deal is sounded out by Takeda shareholders. The Yen/Sterling exchange rate will also affect how valuable Takeda shares are as consideration to UK investors. Finally, the cash part of the consideration offered by Takeda is a fixed dollar amount ($30.33 per share), and so the USD/GBP exchange rate will also impact the value of the takeover offer.
Shire plc’s shares are quoted in Sterling. Currently the share price is £42.18 (as at 22/05/2018), and the takeover value is circa £48.80 (as at 22/05/2018). We think there is a fair chance that the takeover value could go higher still as Takeda’s shares rise. FX rates could also boost the consideration in Sterling terms.
The deal is yet to be approved by Shire and Takeda shareholders. The vote requires 2/3rds of Takeda shareholders to approve the takeover, and 75% of Shire shareholders to vote in favour. But Shire shareholders will be wary of rejecting a deal, given that pharmaceutical giant AstraZeneca plc’s share price (£54.53 as at 22/05/2018) is still below the £55 per share offer from Pfizer that was rejected four years ago in May 2014. Takeda shareholders not in favour of the deal are likely to have sold already.
If shareholders approve the deal, then we see further upside as the gap between the market price and the takeover consideration narrows.
Risk Disclaimer: The value of investments and the income you get from them may fall as well as rise, and there is no certainty that you will get back the amount of your original investment. You should also be aware that past performance may not be a reliable guide to future performance. This document is not intended as investment advice. Any security mentioned in this commentary is for information purposes only and is not a recommendation to buy. Wealth Matters is 4 Shires opinion led commentary. The contents of this webpage are for general information only and do not constitute investment or financial advice. This is not a recommendation to buy or sell any security or to take any action.